




Memorial Sloan Kettering  
Cancer Center™

Opportunities and Approaches for Supplying Molybdenum-99 and  
Associated Medical Isotopes to Global Markets  
IAEA Symposium Vienna Vienna, 2017

# Establishing and Expanding Nuclear Medicine Programs


Wolfgang Weber



# Key existing Applications of $^{99m}\text{Tc}$ Technetium

## Myocardial perfusion imaging for coronary artery disease (CAD)

- Decreased use in the US during the last 5 years due to changes in the reimbursement system
- Still dominates the overall demand for technetium-99m due to the high prevalence of CAD and relatively large amounts of  $^{99m}\text{Tc}$  needed/scan
- Well established evidence supporting its use for
  - Diagnosing CAD
  - Guiding (invasive) therapies
  - Assessing prognosis



# Key existing applications of $^{99m}\text{Tc}$ Technetium

## Bone scans



- Whole body imaging of bone metabolism
  - Detection of bone metastases
  - Several (smaller) indications in benign bone diseases, such as inflammation
- Part of international guidelines for common malignancies, including breast and prostate cancer (e.g. prostate cancer working group criteria).
- Use has decreased because of the success of FDG PET/CT for detection of bone and soft tissue metastases
- Still commonly used in international clinical trials of new pharmaceuticals



# Key existing applications of $^{99m}\text{Tc}$

## Other applications, less commonly used but important

- Sentinel node imaging before surgery of breast cancer, melanoma, ...
- Thyroid scans
- Lung scans
- Renal scans
- Individually less commonly used than bone scans/myocardial perfusion imaging
- However, few (really) competing modalities due to simplicity and cost-effectiveness of the  $^{99m}\text{Tc}$



# Future development of existing applications

## Solid state (CZT) detectors and dedicated camera systems


- Substantially increased sensitivity and spatial resolution of  $^{99m}\text{Tc}$  images
- Faster data acquisition, reduced radiation exposure
- Clinical use has started for myocardial perfusion imaging

## Improved software for data analysis

- Operator independent reporting
- Quantitative instead of qualitative reporting


## Multimodal imaging (SPECT/CT)

- “One stop-shop”



# Bone Scan Index (BSI)



- [Imbriaco M](#) et al: A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res. 1998 4(7):1765-72.
- Time consuming and complex to calculate manually
- Can now be calculated operator independently by imaging processing software
- Objective definition of disease progression in prostate cancer



Automated measurement of BSI

# SPECT/CT with $^{99m}\text{Tc}$ -DPD as "one stop shop" to evaluate of bone pain

"Acute arthritis of the talonavicular joint"



"Something is wrong with the bones of the right foot"




# New developments

- Development of new  $^{99m}\text{Tc}$  labeled pharmaceuticals has been very slow in the last 20 years
- Focus of research was on PET imaging agents because of the higher sensitivity and easier quantification of PET signals
- Unique advantages of  $^{99m}\text{Tc}$  compared to PET radiopharmaceuticals
  - Intraoperative detection/imaging is significantly easier due to lower gamma energy
  - $^{99m}\text{Tc}$  can be used for dual-isotope imaging allowing for multiparametric imaging
  - Longer physical half-life compared to  $^{18}\text{F}$  allows for higher image contrast, radiation exposure is lower than for long-lived PET isotopes
- New camera systems (solid state detectors) and sophisticated reconstruction algorithms are decreasing the difference in sensitivity/quantification of gamma camera imaging as compared to PET





# Imaging of lymphatic drainage with $^{99m}\text{Tc}$ -Tilmanocept



Agrawal et al. MD Anderson Ann Surg Oncol (2015) 22:3708–3715, Fig 1




# Intraoperative free-hand SPECT and ultrasound fusion



Wendler et al. Technical University Munich Eur J Nucl Med Mol Imaging (2010) 37: 1452, Figure 1  
Bluemel et al. University of Wuerzburg, Eur J Nucl Med Mol Imaging (2016) 43:2304, Figure 2



# New Imaging agents labeled with $^{99m}\text{Tc}$

Prostate specific membrane antigen (PSMA) for staging of prostate cancer



Robu et al. Technical University Munich, J Nucl Med 2017, 58:235-242  
Figure 2

# Dual isotope SPECT/CT for detection of endocarditis



Caobelli et al. Eur Heart J 38:436-443, Figure 2,3



# Conclusions

- The medical use of technetium-99m has decreased during the last 10 years due to changes in the reimbursement system and the success of competing imaging modalities (PET/CT, MRI, CT angiography)
- However, there are several indications for which there are no cost-effective alternatives
- New camera systems and new technetium-99m labeled radiopharmaceuticals have the potential to increase the future demand for this radioisotope or at least keep the demand stable

